Epidiolex

Approved Conditions

Epidiolex is specifically indicated for the treatment of seizures associated with the following conditions in patients 1 year of age and older:

• Lennox-Gastaut syndrome: A severe form of epilepsy that typically begins in early childhood and is characterized by multiple types of seizures and developmental delays.
• Dravet syndrome: A rare, lifelong form of epilepsy that begins in infancy and is often associated with prolonged seizures.
• Tuberous sclerosis complex: A genetic disorder that causes noncancerous tumors to grow in various parts of the body, including the brain, which frequently leads to seizures.

This medication is a purified form of cannabidiol (CBD) and is typically prescribed when other treatments have not sufficiently controlled these specific types of seizures. It is often used in combination with other anti-seizure medications.

Mechanism of Action

Epidiolex contains cannabidiol (CBD), which is a chemical compound found in the cannabis plant. While it comes from the same plant as marijuana, it does not contain significant amounts of tetrahydrocannabinol (THC), the substance responsible for a psychoactive high.

The precise way that Epidiolex works to control seizures is currently unknown. However, researchers believe it helps stabilize electrical activity in the brain through several possible pathways:

• Regulating Calcium: It may help control the flow of calcium into nerve cells. Calcium plays a vital role in how these cells send electrical signals.
• Modulating Chemical Signals: It may interact with specific receptors, such as GPR55 and TRPV1, and influence the signaling of adenosine, a chemical that helps regulate brain activity.
• Reducing Hyperexcitability: By affecting these pathways, the medication is thought to reduce the overactive firing of nerve cells that triggers seizures.

Unlike some other cannabis-based products, Epidiolex does not appear to work primarily through the body's main cannabinoid receptors (CB1 and CB2). Instead, it targets different systems in the central nervous system to provide its anticonvulsant effects.

Common Side Effects

Many people taking Epidiolex experience mild to moderate side effects. These often include:

• Drowsiness or extreme sleepiness
• Decreased appetite
• Diarrhea
• Fever
• Feeling tired, weak, or generally unwell
• Skin rash
• Difficulty sleeping or poor sleep quality
• Increased risk of infections

Serious Side Effects

While less common, some side effects require immediate medical attention. Contact a healthcare provider right away if you experience:

Liver Problems

Epidiolex can cause liver injury. Symptoms may include:

• Nausea or vomiting
• Pain in the upper right side of the stomach
• Loss of appetite
• Yellowing of the skin or the whites of the eyes (jaundice)
• Dark urine
• Itching

Mental Health and Mood Changes

Like other anti-seizure medications, Epidiolex may cause suicidal thoughts or actions in a small number of people. Watch for:

• New or worsening depression or anxiety
• Panic attacks
• Agitation, irritability, or aggression
• Impulsivity or restlessness
• Other unusual changes in behavior or mood

Allergic Reactions

Seek emergency help if you notice signs of a severe allergic reaction, such as hives, swelling of the face, lips, or tongue, or difficulty breathing.

Liver Injury

Epidiolex can cause liver problems, often indicated by an increase in liver enzymes. This risk is higher when the medication is taken with other drugs like valproate or clobazam. Healthcare providers typically perform blood tests to check liver function before starting treatment and periodically thereafter.

Suicidal Thoughts and Behavior

Like other medications used to treat seizures, Epidiolex may increase the risk of suicidal thoughts or actions. It is important to monitor for any new or worsening depression, anxiety, or unusual changes in mood or behavior, which can occur shortly after starting the drug.

Somnolence and Sedation

This medication can cause significant sleepiness and sedation, especially when first starting treatment or increasing the dose. Caution is advised when performing tasks that require alertness, such as driving. The risk of sedation increases if Epidiolex is used with alcohol or other drugs that cause drowsiness.

Withdrawal and Seizure Risk

Stopping Epidiolex suddenly can lead to an increase in seizure frequency or severe, continuous seizures. To avoid these complications, the medication is usually discontinued gradually by slowly reducing the dose under medical supervision.

Hypersensitivity Reactions

Serious allergic reactions, including swelling of the face or throat and skin rashes, have been reported. If a severe reaction occurs, the medication should be stopped immediately and medical attention sought.

Pregnancy

There are no adequate and well-controlled studies on the use of Epidiolex in pregnant women to determine drug-associated risks for birth defects, miscarriage, or other adverse outcomes. In animal studies, administration of cannabidiol during pregnancy resulted in decreased fetal body weights and an increase in structural variations at doses lower than the maximum recommended human dose.

Healthcare providers may encourage individuals who become pregnant while taking Epidiolex to enroll in the North American Antiepileptic Drug Pregnancy Registry. This registry collects information to help researchers understand the safety of antiepileptic drugs during pregnancy.

Breastfeeding

It is not known whether Epidiolex passes into human breast milk. Animal studies have shown that cannabidiol is excreted in the milk of lactating animals. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is generally not recommended during treatment with this medication.

Patients should discuss the potential risks and benefits of using this medication while pregnant or breastfeeding with their healthcare provider to make an informed decision.

Dosage Forms

Epidiolex is available in the following form:

• Oral Solution: A liquid medication that is clear and colorless to yellow in appearance.

The medication is packaged with calibrated oral syringes for administration. These syringes are designed to measure the liquid dose accurately. Patients are advised to use the provided measuring devices rather than household spoons to ensure the correct amount of medication is taken.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Epidiolex (cannabidiol) for the treatment of seizures associated with three specific conditions:

• Lennox-Gastaut syndrome
• Dravet syndrome
• Tuberous sclerosis complex

The medication is approved for use in adults and pediatric patients 1 year of age and older.

Regulatory History and Classification

When Epidiolex was first approved in 2018, it was classified by the Drug Enforcement Administration (DEA) as a Schedule V controlled substance. However, in April 2020, the DEA removed Epidiolex from the list of controlled substances. It is no longer subject to the federal Controlled Substances Act, though it remains a prescription-only medication.

Safety and Monitoring

The FDA-approved labeling for Epidiolex does not include a boxed warning, and there is no Risk Evaluation and Mitigation Strategy (REMS) program required. Regulatory oversight focuses on documented risks such as potential liver injury and the risk of suicidal behavior or ideation, which is a standard warning for all antiepileptic medications.

Factors Influencing Cost

The price of Epidiolex is not fixed and can be influenced by several factors:

• Dosage: Because Epidiolex is dosed based on a patient's body weight, the amount of medication needed—and therefore the total cost—will vary significantly between individuals.
• Insurance Coverage: Most commercial insurance plans and government programs like Medicare and Medicaid provide coverage for Epidiolex when it is prescribed for its FDA-approved uses. Out-of-pocket costs such as deductibles and co-pays will depend on the specific plan.
• Pharmacy Choice: Prices may differ between retail pharmacies and specialty pharmacies.

Financial Assistance Programs

The manufacturer of Epidiolex often provides programs to help reduce the financial burden for patients. These may include:

• Co-pay Savings Cards: Eligible patients with commercial insurance may be able to reduce their out-of-pocket costs.
• Patient Assistance Programs: Individuals without insurance or those who are underinsured may qualify for assistance based on financial need.

It is recommended to contact the insurance provider or the manufacturer's support service to get the most accurate estimate of costs and to explore available savings options.